Nasdaq IPOs

nCino, which offers cloud-based software for financial institutions, filed on Monday with the SEC to raise up to $100 million in an initial public offering. With fundamental elements built on the Salesforce platform, the nCino Bank Operating System connects financial institutions

Akouos, a preclinical biotech developing gene therapies for inner ear disorders, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, A

PolyPid, a Phase 3 biotech developing extended-release drugs to prevent surgical site infections, announced terms for its IPO on Monday. This is PolyPid's third attempt to go public. It last filed in February 2018 but withdrew a month later, citing market conditions. The Pet

Fusion Pharmaceuticals, a Phase 1 biotech developing precision medicines for solid tumors, announced terms for its IPO on Monday. The Hamilton, Canada-based company plans to raise $125 million by offering 8.4 million shares at a price range of $14 to $16. At the midpoint of the p

Updated Monday, 6/22. Six IPOs and one SPAC are expected to raise $2 billion in the week ahead, led by grocery giant Albertsons (ACI). Several companies could join the IPO calendar early in the week, such as Lemonade (LMND) and Dun & Bradstreet (DNB).Albertsons Companies

Two IPOs and one SPAC are expected to raise $1.4 billion in the week ahead, led by grocery giant Albertsons (ACI). Chinese tech platform Agora (API) could price this coming week as well. Several companies could join the IPO calendar early in the week, such as PolyPid (PYPD), Fus

Five IPOs and one SPAC went public this past week led by Royalty Pharma (RPRX), which completed the largest US IPO of 2020 to date. Healthcare continued to dominate, with all five IPOs coming from the sector. Royalty Pharma (RPRX) priced its upsized at the high end to raise $2.2

InMed Pharmaceuticals, a Phase 1 developing cannabinoid-based products, filed on Friday with the SEC to raise up to $12 million in an initial public offering. The company is currently is listed on the TSX under the symbol IN and on the OTCQX under the symbol IMLFF. InMed Pharmace

Poseida Therapeutics, a Phase 2 biotech developing CAR T cell therapies for multiple myeloma, filed on Friday with the SEC to raise up to $115 million in an initial public offering. The company previously filed to raise $115 million in January 2019, but withdrew the offering afte

Inventiva, a Phase 2 French biotech developing therapies for NASH and other diseases, filed on Friday with the SEC to raise up to $90 million in an initial public offering. The company's pipeline contains lead candidate lanifibranor, an oral small molecule the

Nkarta, a preclinical biotech developing off-the-shelf cancer therapies based on natural killer cells, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company submitted an IND for its product NKX101 for the treatment of relapsed or refr

Agora, which offers a platform for API development, announced terms for its IPO on Friday. The Shanghai, China-based company plans to raise $298 million by offering 17.5 million ADSs at a price range of $16 to $18. New investor Dragoneer Investment Group intends to purchase $50 m

Greencity Acquisition, a blank check company focused on businesses in Asia, filed on Friday with the SEC to raise up to $40 million in an initial public offering. The Shanghai, China-based company plans to raise $40 million by offering 4 million units at $10. Each unit consists o

Trean Insurance Group, a specialty casualty insurer in the US, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Trean Insurance underwrites specialty casualty insurance products both through programs where it partners with other organization

Progenity, which sells in vitro molecular tests for prenatal and disease screening, raised $100 million by offering 6.7 million shares at $15, within the range of $14 to $16. Progenity plans to list on the Nasdaq under the symbol PROG. Piper Sandler, Wells Fargo Securities, Baird

Genetron Holdings, which provides DNA sequencing-based diagnostic services for cancer patients in China, raised $256 million by offering 16 million ADSs at $16, well above the range of $11.50 to $13.50. The company upsized its offering on Thursday from 13 million ADSs. At pricing

GoHealth, a Medicare-focused health insurance marketplace, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Over the last four years, GoHealth has shifted its focus towards Medicare products over individual and family health insurance produc

Forma Therapeutics, a Phase 1 biotech developing therapies for SCD and hematologic diseases, raised $278 million in an upsized IPO by offering 13.9 million shares at $20, well above the range of $16 to $18. The company originally planned to offer 11.8 million shares. Forma Therap

Repare Therapeutics, a preclinical biotech developing gene therapies for solid tumors, raised $220 million by offering 11 million shares at $20, the high end of the upwardly revised range of $18 to $20. On Wednesday, the company raised the proposed IPO range and offer shares to 1

Albertsons Companies, a US grocer operating under Albertsons, Safeway, and other banners, announced terms for its IPO on Thursday. In its latest filing, the company also added six underwriters. The Boise, ID-based company plans to raise $1.25 billion by offering 65.8 million shar